biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Dec 01, 2015 5:31pm

284 Views

Post# 24344644

RE:RE:News: Bioasis receives patent for blood-brain delivery agent

Narmac,

Today is 12/1. 14 trading days until the AGM on 12/22. My guess is no significant news, if any, until the AGM or within a couple trading days of the AGM. Seems like they are trying to hold back the news, if any, right now. They waited until 11/10 to NR the patent issued on 10/6, and waited until 11/29 to NR the patent issued on 10/20. So at that rate, we wouldn't have a news release for anything that happened today until next year! Of course, I'm being sarcastic. But seriously with it being so close to the AGM, any significant news won't come out until closer to the AGM.

BearDownAZ

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity